Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aldoxorubicin + ifosfamide
- Development stage
- Unknown
- Lead developer
- LadRx
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Aldoxorubicin + ifosfamide is an investigational combination chemotherapy regimen used in clinical trials primarily for advanced or metastatic soft tissue sarcoma. Aldoxorubicin is a tumor-targeted prodrug of doxorubicin, conjugated to albumin, which enables enhanced tumor delivery and reduced cardiotoxicity compared to conventional doxorubicin[8]. Ifosfamide is an alkylating agent that disrupts DNA replication, leading to cancer cell death. The combination leverages the distinct mechanisms of both components to improve antitumor efficacy: aldoxorubicin acts as a DNA intercalator generating free radicals for DNA damage, while ifosfamide alkylates DNA, resulting in cross-linking and cell death. This regimen aims to maximize response rates and progression-free survival compared to single-agent therapy, with ongoing trials assessing its safety and efficacy.
- Other names
- aldoxorubicin and ifosfamide
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on aldoxorubicin + ifosfamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aldoxorubicin + ifosfamide.